-
12:46:59 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

TSOI Stock News

05/27/22 9:00 AM
OTC : TSOI
John Hopkin’s University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
Therapeutic Solutions International, a clinical-stage biotechnology company, commented today on a recent research report from John Hopkins Children's Center in the peer-reviewed publication Nature journal Communications Biology 1. Data generated by the researchers independent of Therapeutic Solutions International, unequivocally demonstrated...
RHEA-AI
neutral
05/23/22 9:00 AM
OTC : TSOI
clinical trial
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial
Therapeutic Solutions International announced today receiving Investigational New Drug application number #28508 from the United States Food and Drug Administration for its proposed clinical trial evaluating the JadiCell™ in treatment of COPD. About Therapeutic Solutions International, Inc.. Therapeutic Solutions International is focused on...
RHEA-AI
neutral
05/12/22 9:00 AM
OTC : TSOI
Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell™ for Treatment of COPD
Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called“ Myeloid Derived Progenitor Cells”. James Veltmeyer, Chief Medical Officer of the Company.“ But in order to even begin talking about cures, we need to realize that a pathology as...
RHEA-AI
neutral
05/09/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells
Therapeutic Solutions International, Inc. announced today filing of an Investigational New Drug application with the United States Food and Drug Administration seeking permission to treat 10 patients with advanced COPD using its universal donor adult stem cell product termed“ JadiCell™”. The Company is currently developing JadiCell as a treatment for...
RHEA-AI
positive
05/02/22 9:00 AM
OTC : TSOI
clinical trialcovid-19
Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Donor Stem Cell Drug
Therapeutic Solutions International announced today the launching of a double-blind, randomized, placebo controlled, multi-center, multi-nation, clinical trial of 128 patients with COVID-19 associated lung failure. The study will be comprised of two groups, JadiCell™ treatment group and control group. “The launch of this clinical trial is a historical step...
RHEA-AI
very positive
04/19/22 9:00 AM
OTC : TSOI
Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell™ to Stimulate Healing of Injured Lung Tissue
Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product induces multiplication of specific lung cells which are believed to give rise to new lung tissue which compensate for damaged cells. “Based on my medical experience, the currently published data on the JadiCells, and what I have personally...
RHEA-AI
negative
03/28/22 9:15 AM
OTC : TSOI
clinical trial
Therapeutic Solutions International Selects Premier Regenerative Medicine CRO Biorasi to Initiate and Run Phase III FDA Registration Clinical Trial for JadiCell™ Universal Donor Adult Stem Cell Product
Therapeutic Solutions International announced today its Board of Directors has selected Biorasi as the contract research organization to run its Pivotal FDA Registration Clinical Trial assessing efficacy of its JadiCell™ Adult Stem Cell Product in patients with advanced COVID-19. “We are enthusiastic to leverage our expertise in the area of cell...
RHEA-AI
neutral
03/25/22 8:00 AM
OTC : TSOI
Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami
Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated lung failure. As part of the trial organization, the Principal Investigator has been changed to Dr. James...
RHEA-AI
neutral